AstraZeneca continues to flounder – Edentree IM

AstraZeneca’s Q4 results have left shareholders disappointed after the pharmaceutical company revealed a 5% fall in revenues for 2016. Ketan Patel, fund manager at EdenTree talks to Portfolio Adviser, claiming that the decision by management to rebuff Pfizer’s premium bid in 2014 will be questioned again following three years of earnings decline.